A Multipeptide Vaccine Plus Toll-Like Receptor Agonists in Melanoma Patients (MEL58)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01585350
Recruitment Status : Completed
First Posted : April 25, 2012
Last Update Posted : August 12, 2016
University of Virginia
National Cancer Institute (NCI)
Oncovir, Inc.
Information provided by (Responsible Party):
Craig L Slingluff, Jr, University of Virginia

No Study Results Posted on for this Study
  Recruitment Status : Completed
  Primary Completion Date : July 2014
  Study Completion Date : October 2014